KR970021093A - 인자 ⅶ 및 활성화된 인자 ⅶ의 정제 방법 - Google Patents

인자 ⅶ 및 활성화된 인자 ⅶ의 정제 방법 Download PDF

Info

Publication number
KR970021093A
KR970021093A KR1019960046225A KR19960046225A KR970021093A KR 970021093 A KR970021093 A KR 970021093A KR 1019960046225 A KR1019960046225 A KR 1019960046225A KR 19960046225 A KR19960046225 A KR 19960046225A KR 970021093 A KR970021093 A KR 970021093A
Authority
KR
South Korea
Prior art keywords
factor vii
factor
thromboplastin
factor viia
soluble
Prior art date
Application number
KR1019960046225A
Other languages
English (en)
Other versions
KR100457984B1 (ko
Inventor
귄터 크루멜
칼-오토 스툼
클라우스-위르겐 피스
페터 하인쯔 루디 리어스
세르게 쁘띠
다니엘 베르나르드
앙리-쟝 꼬펭
준-이찌 가자와라
아끼 아사다
고즈에 시바따
가즈오 가또오
위르겐 뢰미슈
한스-아르놀트 슈퇴르
아네테 포이쓰너
Original Assignee
윌리엄 에이치. 캘넌
아메리칸 사이아나미드 캄파니
쇼쏭 빠트리시아
엘프 아토켐 에스. 에이.
아라우 쟝루이
세까 에스. 에이.
아시다 신
닛뽕 케미카루 리사치 가부시끼가이샤
슈타인, 라우페
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리엄 에이치. 캘넌, 아메리칸 사이아나미드 캄파니, 쇼쏭 빠트리시아, 엘프 아토켐 에스. 에이., 아라우 쟝루이, 세까 에스. 에이., 아시다 신, 닛뽕 케미카루 리사치 가부시끼가이샤, 슈타인, 라우페, 베링베르케 아크티엔게젤샤프트 filed Critical 윌리엄 에이치. 캘넌
Publication of KR970021093A publication Critical patent/KR970021093A/ko
Application granted granted Critical
Publication of KR100457984B1 publication Critical patent/KR100457984B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

본 발명은 고정된 가용성 트롬보플라스틴으로의 결합에 의해 인자 Ⅶ 및/또는 활성화된 인자 Ⅶa(F Ⅶ/F Ⅶa)를 정제하는 방법에 관한 것이다.

Description

인자 Ⅶ 및 활성화된 인자 Ⅶ의 정제 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 인자 Ⅶ 및/또는 인자 Ⅶa-함유 용액을 고정된 가용성 트롬보플라스틴에 결합시킴으로써 이들을 함유하는 용액으로부터 인자 Ⅶ 및/또는 인자 Ⅶa를 제거하는 단계, 세척에 의해 비결합된 분자를 제거하는 단계 및 결합된 인자 Ⅶ 및/또는 인자 Ⅶa를 용출하는 단계들을 포함하는, 인자 Ⅶ 및/또는 인자 Ⅶa의 정제 방법.
  2. 제1항에 있어서, 결합된 인자 Ⅶ 및/또는 인자 Ⅶa를 킬레이트제를 사용하여 용출시키는 방법.
  3. 제1항 또는 제2항에 있어서, Ca2+이온을 0.01 내지 500mM의 농도에서 가하고, 고정된 가용성 트롬보플라스틴으로의 결합과 관련하여 pH 5.0 내지 10.0이 선택되는 방법.
  4. 제2항 또는 제3항에 있어서, 인자 Ⅶ 및/또는 인자 Ⅶa를 용출시키기에 충분한 0.1 내지 1000mM의 농도의 시트레이트, 옥살레이트, 타르트레이트, NTA, EDTA 또는 EGTA를 킬레이트제로서 선택하는 방법.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 기타 간섭 활성 인자를 고정화된 가용성 트롬보플라스틴과 접촉하기 이전에 억제시키는 방법.
  6. 제5항에 있어서, 고정화된 가용성 트롬보플라스틴과 접촉하기 이전에, 안티트롬빈 Ⅲ/헤파린을 부가하여 기타 잠정적인 간섭성 활성화 인자를 불활성화시키고, 경우에 따라, 프로타민 설페이트를 연속해서 부가하는 방법.
  7. 제1항 내지 제6항 중 어느 한 항에 있어서, 가용성 트롬보플라스틴을 비공유 결합에 의해 고체상으로 흡착시키는 방법.
  8. 제7항에 있어서, Fc 단편에 커플링되어진 가용성 트롬보플라스틴을 사용하는 방법.
  9. 제1항 내지 제6항 중 어느 한 항에 있어서, 가용성 트롬보플라스틴을 고체상으로 공유결합시키는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960046225A 1995-10-18 1996-10-16 인자 vii 및 활성화된 인자 vii의 정제방법 KR100457984B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19538715.5 1995-10-18
DE19538715A DE19538715A1 (de) 1995-10-18 1995-10-18 Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
FR9512215 1995-10-18
JP95-300682 1995-10-24
US60/008,022 1995-10-27

Publications (2)

Publication Number Publication Date
KR970021093A true KR970021093A (ko) 1997-05-28
KR100457984B1 KR100457984B1 (ko) 2005-01-31

Family

ID=7775120

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960046225A KR100457984B1 (ko) 1995-10-18 1996-10-16 인자 vii 및 활성화된 인자 vii의 정제방법

Country Status (9)

Country Link
US (1) US6573056B2 (ko)
EP (1) EP0770625B1 (ko)
JP (1) JP3963406B2 (ko)
KR (1) KR100457984B1 (ko)
AT (1) ATE221085T1 (ko)
AU (1) AU706057B2 (ko)
CA (1) CA2188093C (ko)
DE (2) DE19538715A1 (ko)
ES (1) ES2180680T3 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100821644B1 (ko) * 1999-07-14 2008-04-11 노보 노르디스크 헬스 케어 악티엔게젤샤프트 유전자 발현 및 세포 이동 또는 주화성을 조절하기 위한ＦＶＩＩａ 또는 조직 인자 길항제의 사용

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
HUP0402315A3 (en) 2001-12-21 2009-03-30 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
EP3103869A1 (en) * 2003-03-18 2016-12-14 Novo Nordisk Health Care AG Method for the production of factor vii polypeptides
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
AU2004241698A1 (en) 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
CA2534028A1 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP3378470A1 (en) 2003-12-19 2018-09-26 Novo Nordisk Health Care AG Stabilised compositions of factor vii polypeptides
BRPI0514396A2 (pt) 2004-08-17 2009-05-12 Csl Behring Gmbh polipeptìdeos dependentes de vitamina k modificada
EP1797180A2 (en) * 2004-09-29 2007-06-20 Novo Nordisk Health Care AG Purification of a bulk of a factor vii polypeptide by fractionated elution from an anion-exchange material
PL1831242T3 (pl) 2004-12-23 2013-04-30 Novo Nordisk Healthcare Ag Zmniejszanie zawartości zanieczyszczeń białkowych w kompozycjach zawierających zależne od witaminy K białko będące przedmiotem zainteresowania
PL1907540T3 (pl) * 2005-07-22 2013-05-31 Bayer Healthcare Llc Aktywacja czynnika VII w roztworze
WO2007026020A1 (en) * 2005-09-01 2007-03-08 Novo Nordisk Health Care Ag Purification of coagulation factor vii polypeptides
WO2007071767A1 (en) * 2005-12-23 2007-06-28 Novo Nordisk Health Care Ag Purification of vitamin k-dependent polypeptides using preparative reverse phase chromatography (rpc)
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR101492422B1 (ko) 2006-04-11 2015-02-12 체에스엘 베링 게엠베하 치료용 폴리펩타이드의 생체내 회수율을 증가시키는 방법
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880714A (en) 1973-07-18 1975-04-29 Warner Lambert Co Diagnostic reagent
JPS57134419A (en) 1981-02-12 1982-08-19 Eisai Co Ltd Stable anticoagulant of blood
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
DE3150596A1 (de) 1981-12-21 1983-06-30 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von gewebsthromboplastin
US5017556A (en) 1986-11-04 1991-05-21 Genentech, Inc. Treatment of bleeding disorders using lipid-free tissue factor protein
US5118614A (en) 1988-01-18 1992-06-02 Tessek Sdruzeni Praha Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
US5093237A (en) 1988-03-03 1992-03-03 Nippon Shoji Kabushiki Kaisha Method and reagent for determining the biological activity of antithrombin iii by measuring coagulation time
FR2632524B1 (fr) * 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
US5472850A (en) 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
EP0464533B1 (de) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
US5374617A (en) 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
DK38293D0 (da) * 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100821644B1 (ko) * 1999-07-14 2008-04-11 노보 노르디스크 헬스 케어 악티엔게젤샤프트 유전자 발현 및 세포 이동 또는 주화성을 조절하기 위한ＦＶＩＩａ 또는 조직 인자 길항제의 사용

Also Published As

Publication number Publication date
JP3963406B2 (ja) 2007-08-22
EP0770625B1 (de) 2002-07-24
DE19538715A1 (de) 1997-04-30
ATE221085T1 (de) 2002-08-15
US6573056B2 (en) 2003-06-03
AU7022696A (en) 1997-04-24
EP0770625A3 (de) 1998-07-08
CA2188093C (en) 2007-04-24
DE59609474D1 (de) 2002-08-29
JPH09165397A (ja) 1997-06-24
KR100457984B1 (ko) 2005-01-31
AU706057B2 (en) 1999-06-10
US20010007901A1 (en) 2001-07-12
EP0770625A2 (de) 1997-05-02
ES2180680T3 (es) 2003-02-16
CA2188093A1 (en) 1997-04-19

Similar Documents

Publication Publication Date Title
KR970021093A (ko) 인자 ⅶ 및 활성화된 인자 ⅶ의 정제 방법
CA2214633A1 (en) Antibody purification by low-ph hydrophobic interaction chromatography
ATE69310T1 (de) Verfahren zur herstellung eines materials zur affinitaetschromatographie.
ATE236656T1 (de) Eingeschränktes multifunktionelles reagens zur oberflächenmodifikation
SE8200715L (sv) Reduktion av pyrogenhalt
DK0906122T3 (da) Aktiverede linkers og fremgangsmåde til at fremstille og oprense disse
DE59409712D1 (de) Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen
WO1994011032B1 (en) Restrained multifunctional reagent for surface modification
EP0391526A3 (en) Antibody purification process
Funahashi et al. Preparation of three types of heparin-Sepharose and their binding activities to thrombin and antithrombin III
ATE174534T1 (de) Sorption von organischen verbindungen aus gasen
KR850007978A (ko) 섬유질 헤마클루티닌의 정제방법
WO2001002600A3 (en) Detection of analytes using attenuated enzymes
WO1992016292A1 (en) Adsorption matrices
EP0764049B1 (en) Alkali resistant protein adsorbent
ES8705775A1 (es) Un aparato para purificar una corriente de fluido para la eliminacion de ligados transportados en ella
KR960705921A (ko) 사람 활성화 단백질 C제제 및 이의 제조 방법(Human activated protein C preparation and process for producing the same)
AU1856300A (en) Derivatisation of support surfaces
KR860002570A (ko) 백일해 성분 백신 및 백일해항원, 디프테리아 톡소이드 및 파상풍 톡소이드의 혼합백신의 제조방법
De Stefano et al. Metal-chelate regenerable carriers in food processing
NO20001414L (no) FremgangsmÕte ved opprenskning av antitrombin III
US5750065A (en) Adsorption of PCB's using biosorbents
AU2001272736A1 (en) Method of purifying calcium ion-binding protein
Moroi et al. Association of human α1-antitrypsin with anhydrotrypsin
DE3779125D1 (de) Reinigungsmethode fuer antikoerper.

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121019

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20131017

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee